XPO1 and cancer: Preliminary evidence of the in vitro activity of verdinexor has been documented in several canine cancer cell lines and verdinexor exhibits biologic activity in canine lymphoma patients; however, XPO1 expression and therapeutic targeting of XPO1 in canine OS has not been evaluated.23, 28, 29